KMID : 1039420230570040217
|
|
Journal of Pathology and Translational Medicine 2023 Volume.57 No. 4 p.217 ~ p.231
|
|
Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor
|
|
Kim Su-Hwa
Lee Young-Suk Lee Sung-Hak Sung Yeoun-Eun Lee Ah-Won Kang Jun Park Jae-Sung Jeun Sin-Soo Lee Youn-Soo
|
|
Abstract
|
|
|
Background: The metastatic brain tumor is the most common brain tumor. The aim of this study was to demonstrate the clinicopathological and molecular pathologic features of brain metastases (BM).
Methods: A total of 269 patients were diagnosed with BM through surgical resection at Seoul St. Mary¡¯s Hospital from January 2010 to March 2020. We reviewed the clinicopathological features and molecular status of primary and metastatic brain tissues using immunohistochemistry and molecular pathology results.
Results: Among 269 patients, 139 males and 130 females were included. The median age of primary tumor was 58 years (range, 13 to 87 years) and 86 patients (32.0%) had BM at initial presentation. Median BM free interval was 28.0 months (range, 1 to 286 months). The most frequent primary site was lung 46.5% (125/269), and followed by breast 15.6% (42/269), colorectum 10.0% (27/269). Epidermal growth factor receptor (EGFR) mutation was found in 50.8% (32/63) and 58.0% (40/69) of lung primary and BM, respectively. In both breast primary and breast cancer with BM, luminal B was the most frequent subtype at 37.9% (11/29) and 42.9% (18/42), respectively, followed by human epidermal growth factor receptor 2 with 31.0% (9/29) and 33.3% (14/42). Triple-negative was 20.7% (6/29) and 16.7% (7/42), and luminal A was 10.3% (3/29) and 7.1% (3/42) of breast primary and BM, respectively. In colorectal primary and colorectal cancer with BM, KRAS mutation was found in 76.9% (10/13) and 66.7% (2/3), respectively.
Conclusions: We report the clinicopathological and molecular pathologic features of BM that can provide useful information for understanding the pathogenesis of metastasis and for clinical trials based on the tumor¡¯s molecular pathology.
|
|
KEYWORD
|
|
Brain metastases, Clinical pathology, Molecular pathology
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|